Connect with us

Business Wire

Mentor Capital Harvests Half of Market Value in Cash from Side Investments and Reports 30% Q3 Sales Growth

Published

on


Yearly Sales per Share Approach Seven Times Current Share Price

PLANO, Texas–(BUSINESS WIRE)–$Cash #Earnings–Mentor Capital, Inc. (OTCQB: MNTR) announced 25% annualized sales growth to $7,472,367 for the trailing twelve months or $0.33 per share against a share price of $0.05 per share in its quarterly Form 10-Q filing for the third quarter ended September 30, 2022, filed with the Securities and Exchange Commission. During and subsequent to the quarter-end, Mentor collected cash from two maturing side investments totaling $705,370, which exceeds 50% of the Company’s entire public market valuation.

The Company reports that for the nine months ended September 30, 2022, Mentor had revenues of $5,647,817 and a gross profit of $1,723,437, with a resulting net profit attributable to Mentor of (0.1) cents per share. This represents a 34.93% increase in revenue and a 32.20% increase in gross profit over the prior-year quarter ended September 30, 2021, in which Mentor had revenues of $4,185,887 and gross profit of $1,303,612.

On September 30, 2022, the Company had 22,941,357 common shares and 11 Series Q convertible preferred shares outstanding, plus 6,250,000 Series D warrants outstanding with an exercise price of $1.60 per share.

No equity was granted to directors, insiders, consultants, or investor relations firms during the nine quarters ending September 30, 2022. A long-term share repurchase plan was authorized in 2014, and on September 30, 2022, a total of 255,252 shares remain to be repurchased under the plan.

The Company’s shares finished the quarter at a closing price of $0.05 per share, representing a market capitalization of $1,147,068 compared to a 2021 year-end closing price of $0.0508 per share and a corresponding market capitalization of $1,160,828. The Company finished the quarter with a book value of $2,398,466 or $0.10 per share, and a price-to-book ratio of 48% compared to a book value of $2,078,677, at 2021 year-end.

The Series Q Convertible Preferred Stock, for accredited investors, first valued at $10,000 per share on May 30, 2018, was valued at $20,843 per share on September 30, 2022, and 11 Series Q shares could have been converted at a Conversion Price of $0.063 per share into 3,639,262 Mentor common shares, which is an 18.5% compound annual rate of return for each of the last four years.

Beginning in March 2018, Mentor invested $417,664 to facilitate the purchase of manufacturing equipment to be leased to Pueblo West Organics, LLC (“Pueblo West”). As of September 13, 2022, $485,358 had been collected on the lease, and on September 27, 2022, Pueblo West exercised its early lease prepayment option and bought out the lease for $245,369, bringing total collections on the investment to $730,727.

As of the quarter ended September 30, 2022, the Company had invested $396,666 into a Legal Recovery Purchase Agreement with Electrum Partners, LLC against Aurora Cannabis Inc. Subsequent to quarter end, on November 19, 2022, Electrum paid Mentor $460,000 from the proceeds of the Aurora legal recovery. Concurrently, Mentor and Electrum will release and cancel any residual involvement with each other.

As of September 30, 2022, the Company had received $250,000 in loans from the CEO, Chet Billingsley. The loans bear interest at 7.8% per annum, compounded quarterly, and are due upon demand.

The Company is managed by Chairman and CEO Chet Billingsley (70), who founded Mentor Capital first as an acquisition partnership in 1985. Mr. Billingsley’s interest is reported at 8.87% on a fully diluted basis as of September 30, 2022, with other directors and officers holding an additional 6.22% on a fully diluted basis.

The Form 10-Q may be referenced through the SEC’s EDGAR system at: https://www.sec.gov/edgar/searchedgar/companysearch.html or at the Company’s website: www.MentorCapital.com, where additional important information for investors can be found.

About Mentor Capital: The Company seeks to come alongside and assist private companies and their founders and investors in meeting their liquidity, equity financing, and acquisition objectives.

This press release is neither an offer to sell nor a solicitation of offers to purchase securities.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the federal securities laws, including statements concerning financial projections, financing activities, corporate combinations, product development activities, and sales and licensing activities. Such forward-looking statements are not guarantees of future results or performance, and are sometimes identified by words of condition such as “should,” “could,” “expects,” “may,” “intends,” “seeks,” “looks,” “moves,” or “plans” and are subject to a number of risks and uncertainties, known and unknown, that could cause actual results to differ materially from those intended or anticipated. Such risks include, without limitation: nonperformance of investments, partner and portfolio difficulties, potential delays in marketing and sales, problems securing the necessary financing to continue operations, problems involving continued illegality of cannabis products, the potential of competitive products, services, and technologies, difficulties experienced in product development, in recruiting knowledgeable personnel, in protecting intellectual property, and the effects of adverse worldwide economic events, such as the coronavirus recovery and recent step-up in inflation. Further information concerning these and other risks is included in the Company’s Form 10-Q filing, which, along with additional very important details on the Company, can be found here: https://ir.mentorcapital.com/all-sec-filings

The Company undertakes no obligation to update or revise such forward-looking statements to reflect new information, events, or circumstances occurring after the date of this press release.

Contacts

Mentor Capital, Inc.

Chet Billingsley, CEO

(760) 788-4700

info@mentorcapital.com

This post was originally published on this site





Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business Wire

Columbia Care Releases First Corporate Social Responsibility Report

Published

on

By


Impact Report Showcases Company and Community Initiatives Across the U.S.

NEW YORK–(BUSINESS WIRE)–Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S., announced it has released its first-ever Corporate Social Responsibility (CSR) report, Cultivate Impact. The report, which reflects on the past year, highlights local, national and industry initiatives that have made a positive impact specific to the Company’s focus areas: opportunity, inclusion, access and sustainability.

“It is our responsibility as an industry leader to create a mission-driven framework for our company and demonstrate what cannabis and its workforce can do for the world. This report just scratches the surface of how we have strived to do just that,” said Nicholas Vita, CEO and Co-founder, Columbia Care. “I am so proud of the tremendous work our teams have put in across the country to make a difference not only in the cannabis industry but also in the local communities where we operate.”

Columbia Care’s CSR work centers around four key principles: “opportunity”, which focuses on bringing social justice, education and entrepreneurship opportunities to cultivate the inclusive cannabis industry of the future; “inclusion”, which celebrates authenticity and different perspectives that drive the Company and industry forward; “access”, which is a commitment to ending stigmas and ensuring that cannabis is made available to those who need it; and “sustainability”, which creates more sustainable practices through innovation and working with environmentally-responsible partners.

“From social justice to medical accessibility and beyond, we’ve worked diligently from the local neighborhood dispensary level to a multi-state scale to help bring about positive change,” said Ngiste Abebe, VP of Public Policy, Columbia Care. “In addition to our mission-driven employees, we’ve also been really lucky to find strategic partners and vendors who have helped make this work possible. This report is just a start; we look forward to continuing this important work in the future.”

For more information, visit www.columbia.care/about-us/our-impact.

About Columbia Care

Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 17 U.S. jurisdictions. Columbia Care operates 132 facilities including 99 dispensaries and 33 cultivation and manufacturing facilities, including those under development. Columbia Care is one of the original multi-state providers of medical cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the company launched Cannabist, its new retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, Amber and Platinum Label CBD. For more information on Columbia Care, please visit www.columbia.care.

Caution Concerning Forward-Looking Statements

This press release contains certain statements that constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws and reflect the Company’s current expectations regarding future events. Forward-looking statements or information contained in this release include, but are not limited to, statements or information with respect to the Company’s ability to execute on corporate initiatives. These forward-looking statements or information, which although considered reasonable by the Company, may prove to be incorrect and are subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements of the Company to be materially different from those expressed or implied by any forward-looking information. These risks, uncertainties and other factors include, among others, favorable operating and economic conditions; obtaining and maintaining all required licenses and permits; favorable production levels and sustainable costs from the Company’s operations; and the level of demand for cannabis products, including the Company’s products sold by third parties. In addition, securityholders should review the risk factors discussed under “Risk Factors” in Columbia Care’s Form 10 dated May 9, 2022, filed with the applicable securities regulatory authorities and described from time to time in documents filed by the Company with Canadian and U.S. securities regulatory authorities.

Contacts

Investor
Lee Ann Evans

Capital Markets

ir@col-care.com

Media
Lindsay Wilson

Communications

+1.978.662.2038

media@col-care.com

This post was originally published on this site



Source link

Continue Reading

Business Wire

Global Horticulture Lighting Market Report 2022: Strong Government Support for Controlled-Environment Agriculture (CEA) Practices and Adoption of SSL Technology Drives Growth – ResearchAndMarkets.com

Published

on

By


DUBLIN–(BUSINESS WIRE)–The “Global Horticulture Lighting Market with COVID-19 Impact Analysis by Technology (Fluorescent, HID and LED), Application (Greenhouses, Vertical Farms, Indoor Farms), Cultivation, Lighting Type, Offering, Installation and Region – Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The global horticulture lighting market is projected to grow from USD 3.1 billion in 2022 to USD 9.4 billion by 2027; it is expected to grow at a CAGR of 24.5% from 2022 to 2027. The market has a promising growth potential due to several factors, including the technological advancements in LED technology, rising number of government initiatives to promote the adoption of CEA practices, growing demand for food owing to the continuously increasing population, and ongoing legalization of cannabis cultivation. Moreover, increasing the adoption of CEA facilities to meet the growing demand for fresh produce due to COVID-19, and increasing awareness regarding benefits provided by LED technology to grow crops through the year amid the COVID-19 pandemic could play a key role in driving the growth of the horticulture lighting market.

Rising penetration of LED lights in indoor farming due to their long lifespan, spectrum adjustability, and energy efficiency

The LED technology segment is projected to grow at the highest CAGR from 2022 to 2027 for horticulture lighting market, by technology. Energy efficiency continues to be a key factor for the adoption of LED technology in the horticulture sector, along with additional benefits in the form of low heat, long lifespan, light weight, and enhanced controllability. This is expected to boost their adoption across various applications during the forecast period.

Fruits and vegetables is estimated to hold the largest share of the market during the forecast period

The fruits and vegetables segment is projected to account for the largest size of the horticulture lighting market from 2022 to 2027, by cultivation. Increasing demand for quick and fresh horticultural produce owing to population growth and loss of arable land is a key factor driving the growth of this segment of the market. The surging number of vertical farms and greenhouses is also expected to contribute to the growth of this segment of the market.

Asia Pacific is projected to become the fastest geographical market between 2022 and 2027

APAC is projected to grow at the highest CAGR for horticulture lighting market during the forecast period. The growth of the market in this region can be attributed to its continuously increasing population, which leads to rising demand for food from APAC. This has led to an increase in the adoption of advanced farming technologies such as CEA to enable the supply of fresh fruits and vegetables throughout the year. Moreover, high pressure on cultivators to improve agricultural yields with limited available resources and increased requirements to protect crops from unexpected climatic changes are also contributing to the adoption of horticulture lighting in APAC during the forecast period.

Market Dynamics

Drivers

  • Strong Government Support for Controlled-Environment Agriculture (CEA) Practices and Adoption of SSL Technology
  • Heightened Demand for Fresh Food and Loss of Arable Land
  • Increased Investments in Vertical Farms and Greenhouses, Along with Legalization of Cannabis Cultivation
  • Extensive Deployment of Led Fixtures in Controlled Agricultural Environment
  • Widespread Use of Automated and Energy-Efficient Lighting Fixtures to Minimize Energy Costs and Regulate Plant Growth

Restraints

  • High Setup and Installation Costs of Led Horticulture Lights
  • Complex Requirement for Varied Light Spectra for Different Crops

Opportunities

  • Consolidating Trend of Farm-To-Table Concept
  • Promising Growth Opportunities for Vertical Farming Offered by Asian and Middle Eastern Markets
  • Year-Round Crop Production, Irrespective of Weather Conditions
  • Gradual Emergence of Horticulture Lighting Software and Calculators

Challenges

  • Complexities Associated with Deployment of Controlled Environment Agriculture Technology in Large Fields and High Need for Technical Know-How
  • Lack of Standard Testing Practices for Accessing Product Quality of Horticulture Lights and Their Fixtures
  • Effective Integration of Different Components and Technologies Used in CEA Facilities

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Horticulture Lighting Market, by Application

7 Horticulture Lighting Market, by Installation Type

8 Horticulture Lighting Market, by Lighting Type

9 Horticulture Lighting Market, by Offering

10 Horticulture Lighting Market, by Cultivation Type

11 Horticulture Lighting Market, by Technology

12 Geographic Analysis

13 Competitive Landscape

14 Company Profiles

15 Appendix

Companies Mentioned

  • Signify
  • Gavita International B.V.
  • Heliospectra Ab
  • Osram (Part of Ams Ag)
  • California Lightworks
  • Analyst’s View
  • Valoya
  • Lumigrow, Inc.
  • Hortilux Schreder (Dool Industries)
  • Eye Hortilux (An Eye Lighting Division)
  • Iluminar Lighting
  • GE Current, a Daintree Company
  • Parsource
  • GE Lighting, a Savant Company
  • Hubbell
  • Agrolux
  • Econolux
  • Oreon
  • Glaciallight – Lighting Division of Glacialtech
  • Black Dog Grow Technologies Inc.
  • Viparspectra
  • Active Grow LLC
  • Agnetix
  • Thrive Agritech
  • Bridgelux
  • Kroptek

For more information about this report visit https://www.researchandmarkets.com/r/84p5d4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

This post was originally published on this site



Source link

Continue Reading

Business Wire

Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada

Published

on

By


The Research License greatly reduces the timelines required for conducting cannabis research as it eliminates the need for obtaining a project specific cannabis research license

VANCOUVER, British Columbia–(BUSINESS WIRE)–$KONEF #psychedelics–Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), has been awarded an institution wide cannabis research license (the “Research License”) for their new state-of-the-art facility by Health Canada under the Cannabis Act and Cannabis Regulations, allowing the Company to possess cannabis for the purpose of research and development (“R&D”).

The Research License greatly reduces the timelines required for conducting cannabis research and facilitates the ability for KGK to apply for cannabis import permits without first having to obtain project-specific research licenses.

“The Research License allows KGK to conduct clinical trials investigating cannabis for both non-therapeutic and therapeutic purposes, as well as on-site sensory assessments of cannabis products, without having to obtain project specific cannabis research licenses, ultimately accelerating our research programs and reducing the time to market,” added Najla Guthrie, CEO of Wellbeing Digital and KGK Science.

ABOUT KGK SCIENCE

Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

On behalf of:

Najla Guthrie

Chief Executive Officer

WELLBEING DIGITAL SCIENCES

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

Contacts

Natalie Dolphin
VP of Marketing & Investment Relations

Email: ndolphin@wellbeingdigital.co
Twitter: @Wellbeing_IR

This post was originally published on this site





Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media